

Available online at www.sciencedirect.com

# Journal of Hospital Infection

journal homepage: www.elsevier.com/locate/jhin



#### Review

# Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

G. Kampf<sup>a,\*</sup>, D. Todt<sup>b</sup>, S. Pfaender<sup>b</sup>, E. Steinmann<sup>b</sup>

#### ARTICLE INFO

## Article history: Received 31 January 2020 Accepted 31 January 2020 Available online 6 February 2020

Keywords:
Coronavirus
Persistence
Inanimate surfaces
Chemical inactivation
Biocidal agents
Disinfection



#### SUMMARY

Currently, the emergence of a novel human coronavirus, SARS-CoV-2, has become a global health concern causing severe respiratory tract infections in humans. Human-to-human transmissions have been described with incubation times between 2-10 days, facilitating its spread via droplets, contaminated hands or surfaces. We therefore reviewed the literature on all available information about the persistence of human and veterinary coronaviruses on inanimate surfaces as well as inactivation strategies with biocidal agents used for chemical disinfection, e.g. in healthcare facilities. The analysis of 22 studies reveals that human coronaviruses such as Severe Acute Respiratory Syndrome (SARS) coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus or endemic human coronaviruses (HCoV) can persist on inanimate surfaces like metal, glass or plastic for up to 9 days, but can be efficiently inactivated by surface disinfection procedures with 62-71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 minute. Other biocidal agents such as 0.05-0.2% benzalkonium chloride or 0.02% chlorhexidine digluconate are less effective. As no specific therapies are available for SARS-CoV-2, early containment and prevention of further spread will be crucial to stop the ongoing outbreak and to control this novel infectious thread.

© 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

#### Introduction

A novel coronavirus (SARS-CoV-2) has recently emerged from China with a total of 45171 confirmed cases of pneumonia (as of February 12, 2020) [1]. Together with Severe Acute Respiratory Syndrome (SARS) coronavirus and Middle East Respiratory Syndrome (MERS) coronavirus [2], this is the third highly pathogenic human coronavirus that has emerged in the last two decades. Person-to-person transmission has been described both in hospital and family settings [3]. It is therefore of utmost importance to prevent any further

spread in the public and healthcare settings. Transmission of coronaviruses from contaminated dry surfaces has been postulated including self-inoculation of mucous membranes of the nose, eyes or mouth [4,5], emphasizing the importance of a detailed understanding of coronavirus persistence on inanimate surfaces [6]. Various types of biocidal agents such as hydrogen peroxide, alcohols, sodium hypochlorite or benzalkonium chloride are used worldwide for disinfection, mainly in healthcare settings [7]. The aim of the review was therefore to summarize all available data on the persistence of all coronaviruses including emerging SARS-CoV and MERS-CoV as well as veterinary coronaviruses such as transmissible gastroenteritis virus (TGEV), mouse hepatitis virus (MHV) and canine coronavirus (CCV) on different types of

E-mail address: guenter.kampf@uni-greifswald.de (G. Kampf).

<sup>&</sup>lt;sup>a</sup> University Medicine Greifswald, Institute for Hygiene and Environmental Medicine, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany

<sup>&</sup>lt;sup>b</sup> Department of Molecular and Medical Virology, Ruhr University Bochum, Universitätsstrasse 50, 44801 Bochum, Germany

<sup>\*</sup> Corresponding author.

inanimate surfaces and on the efficacy of commonly used biocidal agents used in surface disinfectants against coronaviruses.

#### Method

A Medline search has been done on January 28, 2020. The following terms were used, always in combination with "coronavirus", "TGEV", "MHV" or "CCV": survival surface (88 / 10 / 25 / 0 hits), persistence surface (47 / 1 / 32 / 0 hits), persistence hand (8 / 0 / 3 / 0 hits), survival hand (22 / 0 / 3 / 1 hits), survival skin (8 / 0 / 0 / 1 hits), persistence skin (1 / 0 / 0 / 1 hit), virucidal (23 / 3 / 3 / 1 hits), chemical inactivation (33 / 0 / 6 / 1), suspension test (18 / 0 / 0 / 0 hits) and carrier test (17 / 4 / 0 / 0 hits). Publications were included and results were extracted given they provided original data on coronaviruses on persistence (surfaces, materials) and inactivation by biocidal agents used for disinfection (suspension tests, carrier tests, fumigation studies). Data with commercial products based on various different types of biocidal agents were excluded. Reviews were not included, but screened for any information within the scope of this review.

#### **Results**

#### Persistence of coronavirus on inanimate surfaces

Most data were described with the endemic human coronavirus strain (HCoV-) 229E. On different types of materials it can remain infectious for from 2 hours up to 9 days. A higher temperature such as 30°C or 40°C reduced the duration of persistence of highly pathogenic MERS-CoV, TGEV and MHV. However, at 4°C persistence of TGEV and MHV can be increased to  $\geq$  28 days. Few comparative data obtained with SARS-CoV indicate that persistence was longer with higher inocula (Table I). In addition it was shown at room temperature that HCoV-229E persists better at 50% compared to 30% relative humidity [8].

# Inactivation of coronaviruses by biocidal agents in suspension tests

Ethanol (78–95%), 2-propanol (70–100%), the combination of 45% 2-propanol with 30% 1-propanol, glutardialdehyde (0.5-2.5%), formaldehyde (0.7-1%) and povidone iodine

**Table I**Persistence of coronaviruses on different types of inanimate surfaces

Type of surface	Virus	Strain / isolate	Inoculum (viral titer)	Temperature	Persistence	Reference
Steel	MERS-CoV	Isolate HCoV-EMC/2012	10 <sup>5</sup>	20°C	48 h	[21]
				30°C	8-24 h	
	TGEV	Unknown	10 <sup>6</sup>	4°C	$\geq$ 28 d	[22]
				20°C	3-28 d	
				40°C	4–96 h	
	MHV	Unknown	10 <sup>6</sup>	4°C	$\geq$ 28 d	[22]
				20°C	4-28 d	
				40°C	4–96 h	
	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]
Aluminium	HCoV	Strains 229E and OC43	5 x 10 <sup>3</sup>	21°C	2-8 h	[24]
Metal	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	5 d	[25]
Wood	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	4 d	[25]
Paper	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	4-5 d	[25]
·	SARS-CoV	Strain GVU6109	10 <sup>6</sup>	RT	24 h	[26]
			10 <sup>5</sup>		3 h	
			10 <sup>4</sup>		< 5 min	
Glass	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	4 d	[25]
	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]
Plastic	SARS-CoV	Strain HKU39849	10 <sup>5</sup>	22°-25°C	$\leq$ 5 d	[27]
	MERS-CoV	Isolate HCoV-EMC/2012	10 <sup>5</sup>	20°C	48 h	[21]
				30°C	8-24 h	
	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	4 d	[25]
	SARS-CoV	Strain FFM1	10 <sup>7</sup>	RT	6-9 d	[28]
	HCoV	Strain 229E	10 <sup>7</sup>	RT	2-6 d	[28]
PVC	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]
Silicon rubber	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]
Surgical glove (latex)	HCoV	Strains 229E and OC43	5 x 10 <sup>3</sup>	21°C	≤ 8 h	[24]
Disposable gown	SARS-CoV	Strain GVU6109	10 <sup>6</sup>	RT	2 d	[26]
			10 <sup>5</sup>		24 h	
			10 <sup>4</sup>		1 h	
Ceramic	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]
Teflon	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]

 $MERS = Middle \ East \ Respiratory \ Syndrome; \ HCoV = human \ coronavirus; \ TGEV = transmissible \ gastroenteritis \ virus; \ MHV = mouse \ hepatitis \ virus; \ SARS = Severe \ Acute \ Respiratory \ Syndrome; \ RT = room \ temperature.$ 

**Table II**Inactivation of coronaviruses by different types of biocidal agents in suspension tests

				viral infectivity (log <sub>10</sub> )	
95%	SARS-CoV	 Isolate FFM-1	30 s	$\geq 5.5$	[29]
85%	SARS-COV	Isolate FFM-1	30 s	≥ 5.5 ≥ 5.5	
					[29]
					[29]
					[14]
					[28]
70%	MHV	Strains MHV-2 and MHV-N	10 min	> 3.9	[30]
70%	CCV	Strain I-71	10 min	> 3.3	[30]
100%	SARS-CoV	Isolate FFM-1	30 s	<b>≥ 3.3</b>	[28]
<b>75</b> %	SARS-CoV	Isolate FFM-1	30 s	> 4.0	[14]
		Strain EMC			[14]
					[28]
					[30]
				,	,
50%	CCV		10 min	> 3.7	[30]
					[29]
45% and 50%					[28]
0.2%					
0.2/0	псоу		10 111111	0.0	[31]
0.050/	441.157	,	40	. 2.7	[20]
0.05%	MHV		10 min	> 3.7	[30]
2 250/					
					[30]
					[32]
0.0025%	CCV	Strain S378	3 d	> 4.0	[32]
0.02%	MHV	Strains MHV-2	10 min	0.7-0.8	[30]
		and MHV-N			
0.02%	CCV	Strain I-71	10 min	0.3	[30]
	MHV	Strain MHV-1			[33]
0.01%	MHV	Strains MHV-2	10 min	2.3–2.8	[30]
0.01%	CCV		10 min	1 1	[20]
					[30]
		and MHV-N	10 min		[30]
0.001%		Strain I-71	10 min	0.9	[30]
0.5%	HCoV	Strain 229E	1 min	> 4.0	[34]
1%	SARS-CoV	Isolate FFM-1	2 min	> 3.0	[28]
0.7%	SARS-CoV	Isolate FFM-1	2 min	> 3.0	[28]
0.7%	MHV		10 min	> 3.5	[30]
0.7%	CCV	Strain I-71	10 min	> 3.7	[30]
			24 h	> 4.0	[35]
		Hanoi strain			[36]
					[28]
					[37]
					[37]
					[36]
					[37]
					[36]
					[36]
					[36]
				_	[38] [38]
	100% 75% 75% 70% 50% 50% 45% and 30% 0.2% 0.05% 0.00175% 0.0025% 0.02% 0.02% 0.01% 0.01% 0.001% 0.001% 0.5% 1% 0.7%	80%       MERS-CoV         78%       SARS-CoV         70%       CCV         100%       SARS-CoV         75%       SARS-CoV         75%       MERS-CoV         70%       SARS-CoV         70%       SARS-CoV         50%       CCV         45% and 30%       SARS-CoV         SARS-CoV       SARS-CoV         0.05%       CCV         0.00175%       CCV         0.002%       CCV         0.02%       CCV         0.21%       MHV         0.02%       CCV         0.21%       MHV         0.01%       CCV         0.01%       CCV         0.01%       MHV         0.01%       CCV         0.001%       CCV         0.001%       CCV         0.7%       SARS-CoV         0.7%       SARS-CoV         0.5%       SARS-CoV	80%         MERS-CoV         Strain EMC           78%         SARS-COV         Isolate FFM-1           70%         MHV         Strains MHV-2           and MHV-N         Strain I-71           100%         SARS-COV         Isolate FFM-1           75%         SARS-COV         Isolate FFM-1           75%         MERS-COV         Strain EMC           70%         SARS-COV         Isolate FFM-1           50%         MHV         Strains MHV-2           and MHV-N         Strain I-71           45% and 30%         SARS-COV         Isolate FFM-1           50%         CCV         Strain I-71           45% and 30%         SARS-COV         Isolate FFM-1           50%         CCV         Strain I-71           45% and 30%         SARS-COV         Isolate FFM-1           0.2%         HCOV         ATCC VR-759           (strain OC43)         Strain OC43)           0.05%         MHV         Strain S378           0.00175%         CCV         Strain S378           0.0025%         CCV         Strain S378           0.0026         CCV         Strain S4NHV-2           and MHV-N         Strain S378	80%         MERS-COV         Strain EMC         30 s           78%         SARS-COV         Isolate FFM-1         30 s           70%         MHV         Strain SMHV-2         10 min           70%         CCV         Strain I-71         10 min           100%         SARS-COV         Isolate FFM-1         30 s           75%         SARS-COV         Isolate FFM-1         30 s           75%         MERS-COV         Strain EMC         30 s           70%         SARS-COV         Isolate FFM-1         30 s           50%         MHV         Strains MHV-2         10 min           45% and 30%         SARS-COV         Isolate FFM-1         30 s           50%         CCV         Strain I-71         10 min           45% and 30%         SARS-COV         Isolate FFM-1         30 s           0.2%         HCOV         ATCC VR-759         10 min           0.02%         HCOV         ATCE VR-759         10 min           0.05%         MHV         Strain I-71         10 min           0.0175%         CCV         Strain I-71         10 min           0.00175%         CCV         Strain SARB         3 d           0.00175%	80%         MERS-COV         Strain EMC         30 s         > 4.0           78%         SARS-COV         Isolate FFM-1         30 s         > 5.0           70%         CV         Strain I-71         10 min         > 3.9           70%         CCV         Strain I-71         10 min         > 3.3           100%         SARS-CoV         Isolate FFM-1         30 s         > 24.0           75%         MERS-COV         Strain EMC         30 s         > 24.0           75%         MERS-COV         Strain EMC         30 s         > 24.0           75%         MERS-COV         Strain EMC         30 s         > 24.0           75%         MERS-COV         Isolate FFM-1         30 s         > 3.3           50%         MHV         Strain SMHV-2         10 min         > 3.7           45% and 30%         SARS-COV         Isolate FFM-1         30 s         > 2.8           0.2%         HCOV         ATCC VR-759         10 min         > 3.7           45% and 30%         SARS-COV         Isolate FFM-1         30 s         > 2.8           0.2%         CCV         Strain I-71         10 min         > 3.7           0.2%         CCV         Stra

 $SARS = Severe \ Acute \ Respiratory \ Syndrome; \ MERS = Middle \ East \ Respiratory \ Syndrome; \ MHV = mouse \ hepatitis \ virus; \ CCV = canine \ coronavirus; \ HCoV = human \ coronavirus.$ 

**Table III**Inactivation of coronaviruses by different types of biocidal agents in carrier tests

Biocidal agent	Concentration	Virus	Strain / isolate	Volume / material	Organic load	Exposure time	Reduction of viral	Reference
							infectivity	
							$(\log_{10})$	
Ethanol	71%	TGEV	Unknown	50 μl / stainless steel	None	1 min	3.5	[39]
	71%	MHV	Unknown	$50 \mu l$ / stainless steel	None	1 min	2.0	[39]
	70%	TGEV	Unknown	50 μl / stainless steel	None	1 min	3.2	[39]
	70%	MHV	Unknown	50 μl / stainless steel	None	1 min	3.9	[39]
	70%	HCoV	Strain 229E	20 μl / stainless steel	5% serum	1 min	> 3.0	[40]
	62%	TGEV	Unknown	50 μl / stainless steel	None	1 min	4.0	[39]
	62%	MHV	Unknown	50 μl / stainless steel	None	1 min	2.7	[39]
Benzalkoniumchloride	0.04%	HCoV	Strain 229E	20 μl / stainless steel	5% serum	1 min	< 3.0	[40]
Sodium hypochlorite	0.5%	HCoV	Strain 229E	20 μl / stainless steel	5% serum	1 min	> 3.0	[40]
	0.1%	HCoV	Strain 229E	20 μl / stainless steel	5% serum	1 min	> 3.0	[40]
	0.06%	TGEV	Unknown	50 μl / stainless steel	None	1 min	0.4	[39]
	0.06%	MHV	Unknown	50 μl / stainless steel	None	1 min	0.6	[39]
	0.01%	HCoV	Strain 229E	20 μl / stainless steel	5% serum	1 min	< 3.0	[40]
Glutardialdehyde	2%	HCoV	Strain 229E	20 μl / stainless steel	5% serum	1 min	> 3.0	[40]
Ortho-phtalaldehyde	0.55%	TGEV	Unknown	50 $\mu$ l / stainless steel	None	1 min	2.3	[39]
	0.55%	MHV	Unknown	$50 \mu l$ / stainless steel	None	1 min	1.7	[39]
Hydrogen peroxide	Vapor of unknown concentration	TGEV	Purdue strain type 1	20 μl / stainless steel	None	2-3 h	4.9-5.3*	[41]

TGEV = transmissible gastroenteritis virus; MHV = mouse hepatitis virus; HCoV = human coronavirus; \*depending on the volume of injected hydrogen peroxide.

(0.23–7.5%) readily inactivated coronavirus infectivity by approximately 4 log<sub>10</sub> or more. (Table II). Sodium hypochlorite required a minimal concentration of at least 0.21% to be effective. Hydrogen peroxide was effective with a concentration of 0.5% and an incubation time of 1 min. Data obtained with benzalkonium chloride at reasonable contact times were conflicting. Within 10 min a concentration of 0.2% revealed no efficacy against coronavirus whereas a concentration of 0.05% was quite effective. 0.02% chlorhexidine digluconate was basically ineffective (Table II).

# Inactivation of coronaviruses by biocidal agents in carrier tests

Ethanol at concentrations between 62% and 71% reduced coronavirus infectivity within 1 min exposure time by 2.0–4.0  $\log_{10}$ . Concentrations of 0.1–0.5% sodium hypochlorite and 2% glutardialdehyde were also quite effective with > 3.0  $\log_{10}$  reduction in viral titre. In contrast, 0.04% benzalkonium chloride, 0.06% sodium hypochlorite and 0.55% orthophtalaldehyde were less effective (Table III).

#### Discussion

Human coronaviruses can remain infectious on inanimate surfaces at room temperature for up to 9 days. At a temperature of 30°C or more the duration of persistence is shorter. Veterinary coronaviruses have been shown to persist even longer for 28 d. Contamination of frequent touch surfaces in healthcare settings are therefore a potential source of viral transmission. Data on the transmissibility of coronaviruses from contaminated surfaces to hands were not found. However, it could be shown with influenza A virus that a contact of 5 s can transfer 31.6% of the viral load to the hands [9]. The transfer efficiency was lower (1.5%) with parainfluenza virus 3 and a 5 s contact between the surface and the hands [10]. In an observational study, it was described that students touch their face with their own hands on average 23 times per h, with contact mostly to the skin (56%), followed by mouth (36%), nose (31%) and eyes (31%) [11]. Although the viral load of coronaviruses on inanimate surfaces is not known during an outbreak situation it seem plausible to reduce the viral load on surfaces by disinfection, especially of frequently touched surfaces in the immediate patient surrounding where the highest viral load can be expected. The WHO recommends "to ensure that environmental cleaning and disinfection procedures are followed consistently and correctly. Thoroughly cleaning environmental surfaces with water and detergent and applying commonly used hospital-level disinfectants (such as sodium hypochlorite) are effective and sufficient procedures." [12] The typical use of bleach is at a dilution of 1:100 of 5% sodium hypochlorite resulting in a final concentration of 0.05% [13]. Our summarized data with coronaviruses suggest that a concentration of 0.1% is effective in 1 min (Table III). That is why it seems appropriate to recommend a dilution 1:50 of standard bleach in the coronavirus setting. For the disinfection of small surfaces ethanol (62-71%; carrier tests) revealed a similar efficacy against coronavirus. A concentration of 70% ethanol is also recommended by the WHO for disinfecting small surfaces [13].

No data were found to describe the frequency of hands becoming contaminated with coronavirus, or the viral load on hands either, after patient contact or after touching contaminated surfaces. The WHO recommends to preferably apply alcohol-based hand rubs for the decontamination of hands, e.g. after removing gloves. Two WHO recommended formulations (based on 80% ethanol or 75% 2-propanol) have been evaluated in suspension tests against SARS-CoV and MERS-CoV. and both were described to be very effective [14]. No in vitro data were found on the efficacy of hand washing against coronavirus contaminations on hands. In Taiwan, however, it was described that installing hand wash stations in the emergency department was the only infection control measure which was significantly associated with the protection from healthcare workers from acquiring the SARS-CoV, indicating that hand hygiene can have a protective effect [15]. Compliance with hand hygiene can be significantly higher in an outbreak situation but is likely to remain an obstacle especially among physicians [16–18]. Transmission in healthcare settings can be successfully prevented when appropriate measures are consistently performed [19,20].

## **Conclusions**

Human coronaviruses can remain infectious on inanimate surfaces for up to 9 days. Surface disinfection with 0.1% sodium hypochlorite or 62—71% ethanol significantly reduces coronavirus infectivity on surfaces within 1 min exposure time. We expect a similar effect against the SARS-CoV-2.

Conflict of interest statement None declared.

Funding Sources None.

## References

- [1] WHO. Coronavirus Disease 2019 (COVID-19). WHO; 2020. Situation Report 23.
- [2] de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523—34.
- [3] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020. https://doi.org/10.1016/s0140-6736(20) 30154-9.
- [4] Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect 2016;92:235–50.
- [5] Dowell SF, Simmerman JM, Erdman DD, Wu JS, Chaovavanich A, Javadi M, et al. Severe acute respiratory syndrome coronavirus on hospital surfaces. Clin Infect Dis 2004;39:652—7.
- [6] Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses 2012;4:3044–68.
- [7] Kampf G. Antiseptic stewardship: biocide resistance and clinical implications. Cham: Springer International Publishing; 2018.
- [8] Ijaz MK, Brunner AH, Sattar SA, Nair RC, Johnson-Lussenburg CM. Survival characteristics of airborne human coronavirus 229E. J Gen Virol 1985;66(Pt 12):2743-8.
- [9] Bean B, Moore BM, Sterner B, Peterson LR, Gerding DN, Balfour HH. Survival of influenza viruses an environmental surfaces. J Infect Dis 1982;146:47—51.

- [10] Ansari SA, Springthorpe VS, Sattar SA, Rivard S, Rahman M. Potential role of hands in the spread of respiratory viral infections: studies with human parainfluenza virus 3 and rhinovirus 14. J Clin Microbiol 1991;29:2115—9.
- [11] Kwok YL, Gralton J, McLaws ML. Face touching: a frequent habit that has implications for hand hygiene. Am J Infect Contr 2015;43:112-4.
- [12] WHO. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. WHO; 2020. Interim guidance. 25 January 2020.
- [13] WHO. Annex G. Use of disinfectants: alcohol and bleach. Infection prevention and control of epidemic-and pandemic-prone acute respiratory infections in health care. Geneva: WHO; 2014. p. 65–6.
- [14] Siddharta A, Pfaender S, Vielle NJ, Dijkman R, Friesland M, Becker B, et al. Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. J Infect Dis 2017;215:902-6.
- [15] Yen MY, Lu YC, Huang PH, Chen CM, Chen YC, Lin YE. Quantitative evaluation of infection control models in the prevention of nosocomial transmission of SARS virus to healthcare workers: implication to nosocomial viral infection control for healthcare workers. Scand J Infect Dis 2010;42:510—5.
- [16] Alshammari M, Reynolds KA, Verhougstraete M, O'Rourke MK. Comparison of perceived and observed hand hygiene compliance in healthcare workers in MERS-CoV endemic regions. Healthcare (Basel, Switzerland) 2018;6:122.
- [17] Al-Tawfiq JA, Abdrabalnabi R, Taher A, Mathew S, Rahman KA. Infection control influence of Middle East respiratory syndrome coronavirus: A hospital-based analysis. Am J Infect Contr 2019;47:431—4.
- [18] Wong TW, Tam WW. Handwashing practice and the use of personal protective equipment among medical students after the SARS epidemic in Hong Kong. Am J Infect Contr 2005;33:580-6.
- [19] Wiboonchutikul S, Manosuthi W, Likanonsakul S, Sangsajja C, Kongsanan P, Nitiyanontakij R, et al. Lack of transmission among healthcare workers in contact with a case of Middle East respiratory syndrome coronavirus infection in Thailand. Antimicrob Resist Infect Control 2016:5:21.
- [20] Ki HK, Han SK, Son JS, Park SO. Risk of transmission via medical employees and importance of routine infection-prevention policy in a nosocomial outbreak of Middle East respiratory syndrome (MERS): a descriptive analysis from a tertiary care hospital in South Korea. BMC Pulm Med 2019;19:190.
- [21] van Doremalen N, Bushmaker T, Munster VJ. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. Euro Surveill 2013;18.
- [22] Casanova LM, Jeon S, Rutala WA, Weber DJ, Sobsey MD. Effects of air temperature and relative humidity on coronavirus survival on surfaces. Appl Environ Microbiol 2010;76:2712—7.
- [23] Warnes SL, Little ZR, Keevil CW. Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials. mBio 2015;6:e01697—15.
- [24] Sizun J, Yu MW, Talbot PJ. Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible

- source of hospital-acquired infections. J Hosp Infect 2000;46:55-60.
- [25] Duan SM, Zhao XS, Wen RF, Huang JJ, Pi GH, Zhang SX, et al. Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. Biomed Environ Sci 2003;16:246–55.
- [26] Lai MY, Cheng PK, Lim WW. Survival of severe acute respiratory syndrome coronavirus. Clin Infect Dis 2005;41:e67–71.
- [27] Chan KH, Peiris JS, Lam SY, Poon LL, Yuen KY, Seto WH. The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. Adv Virol 2011;734690.
- [28] Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW. Stability and inactivation of SARS coronavirus. Med Microbiol Immunol 2005;194:1-6.
- [29] Rabenau HF, Kampf G, Cinatl J, Doerr HW. Efficacy of various disinfectants against SARS coronavirus. J Hosp Infect 2005;61:107—11.
- [30] Saknimit M, Inatsuki I, Sugiyama Y, Yagami K. Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals. Jikken Dobutsu Exp Anim 1988:37:341—5.
- [31] Wood A, Payne D. The action of three antiseptics/disinfectants against enveloped and non-enveloped viruses. J Hosp Infect 1998;38:283—95.
- [32] Pratelli A. Action of disinfectants on canine coronavirus replication in vitro. Zoonoses Publ Health 2007;54:383—6.
- [33] Dellanno C, Vega Q, Boesenberg D. The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus. Am J Infect Control 2009;37:649–52.
- [34] Omidbakhsh N, Sattar SA. Broad-spectrum microbicidal activity, toxicologic assessment, and materials compatibility of a new generation of accelerated hydrogen peroxide-based environmental surface disinfectant. Am J Infect Control 2006;34:251-7.
- [35] Pratelli A. Canine coronavirus inactivation with physical and chemical agents. Vet J (London, England: 1997) 2008;177:71–9.
- [36] Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatol (Basel, Switzerland) 2006;212(Suppl 1):119—23.
- [37] Eggers M, Eickmann M, Zorn J. Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA). Infect Dis Ther 2015;4:491—501.
- [38] Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/ Mouthwash Against Respiratory and Oral Tract Pathogens. Infect Dis Ther 2018;7:249—59.
- [39] Hulkower RL, Casanova LM, Rutala WA, Weber DJ, Sobsey MD. Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. Am J Infect Control 2011;39:401—7.
- [40] Sattar SA, Springthorpe VS, Karim Y, Loro P. Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses. Epidemiol Infect 1989;102:493–505.
- [41] Goyal SM, Chander Y, Yezli S, Otter JA. Evaluating the virucidal efficacy of hydrogen peroxide vapour. J Hosp Infect 2014;86:255—9.